Add-on Vitamin E in Improving Treatment Outcomes in Diabetic Peripheral Neuropathy: A Prospective Interventional Study
DOI:
https://doi.org/10.37506/z8mscq23Keywords:
Vitamin E, Diabetic Peripheral Neuropathy, Add-on Treatment.Abstract
Background: Neuropathy is one of the most common long-standing complications of diabetes, affecting over 50% of the diabetic individuals. Managing DPN and its complications involves comprehensive care and a multidisciplinary approach. Besides pharmacological treatments, botanicals and dietary supplements that have also been found to improve symptoms of DPN without affecting glucose control. The possible role of vitamin E in the management of DPN have been postulated in various studies. The present study thus aimed to prospectively assess whether add-on treatment with vitamin E can improve treatment outcomes in diabetic peripheral neuropathy.
Methods: The study included newly diagnosed patients with diabetic peripheral neuropathy for a period of initial two months. Patients were randomly allocated to either standard treatment Group (Group A) or the intervention
Group (Group B). As a part of intervention, patients received vitamin E 400mg once daily in addition to the
standard of care. Efficacy Parameters measured at baseline, 6 months and 12 months included changes in visual analog scoring, mean pain score, brief pain inventory and patient’s global impression of change. Treatment safety, quality of life and treatment adherence was assessed. Data was statistically analysed.
Result: The study included a total of 100 patients, 50 patients in each Group. Significantly higher decrease of glycaemic measures was noted for Group B compared to Group A in terms of PPPG and serum creatinine, however, there was comparable change in HbA1c and FPG for both Groups. There was comparable significant reduction in mean VAS scoring at 6 and 12 months for Group B. Considering all the efficacy measures, there was highest reduction for the pain interference in the intervention arm (Group B), in comparison to Group A. (p<0.001). Quality of life measures and mean adherence scoring significantly increased for treatment group B as compared to A at both 6 months and 12 months of study assessments. No major safety concerns were reported during the study period.
Conclusion: Our study noted that addition of vitamin E as an added supplementation to the standard of care
showed benefits in terms of patient reported reduced pain interference and pain perception, which also significantly improved overall quality of life in these patients.
References
Dyck PJ, Katz KM, Karnes JL, Litchy WJ, Klein R, Pach
JM: The prevalence by staged severity of various types
of diabetic neuropathy, retinopathy and nephropathy
in a population-based cohort: the Rochester Diabetic
Neuropathy study. Neurology 43:817 -824, 1993
Young MJ, Boulton AJM, McLeod AF, Williams DRR,
Sonksen PH: A multicentre study of the prevalence
of diabetic peripheral neuropathy in the UK hospital
clinic population. Diabetologia 36:150 -156, 1993
Kumar S, Ashe HC, Parnell LN, Fernando DJS, Tsigos
C, Young RJ, Ward JD, Boulton AJM: The prevalence
of foot ulceration and its correlates in type 2 diabetes:
a population-based study. Diabetic Med11 : 480-
,1994
Cabezas-Cerrato J: The prevalence of diabetic
neuropathy in Spain: a study in primary care and
hospital clinic groups. Diabetologia41 : 1263-1269,1998
Boulton AJM, Malik RA, Arezzo JC, Sosenko
JM: Diabetic somatic neuropathies: a technical
review. Diabetes Care 27:1458 -1486, 2004
Gibbons CH, Freeman R: Treatment-induced
diabetic neuropathy: a reversible painful autonomic
neuropathy. Ann Neurol. 2010; 67(4): 534–41.
England JD, Gronseth GS, Franklin G, et al.: Practice
parameter: the evaluation of distal symmetric
polyneuropathy: the role of autonomic testing, nerve
biopsy, and skin biopsy (an evidence-based review).
Report of the American Academy of Neurology,
the American Association of Neuromuscular and
Electrodiagnostic Medicine, and the American
Academy of Physical Medicine and Rehabilitation. PM
R. 2009; 1(1): 14–22.
Beulens JW, Hart HE, Kuijs R, et al.: Influence
of duration and dose of metformin on cobalamin
deficiency in type 2 diabetes patients using metformin.
Acta Diabetol. 2015; 52(1): 47–53
Cohen K, Shinkazh N, Frank J, Israel I, Fellner C.
Pharmacological treatment of diabetic peripheral
neuropathy. P T. 2015;40(6):372–388.
Connell SO. Select vitamins and minerals in the
management of diabetes. Diabetes Spectr. 2001;14:133–
Tutuncu NB, Bayraktar N, Varli K. Reversal of defective
nerve conduction with vitamin E supplementation in
type 2 diabetes. Diabet Care. 1998;21:1915–8.
Jamal GA, Carmichael H. The effect of gamma-linolenic
acid on human diabetic neuropathy: A double-blind
placebo–controlled trial. Diabet Met. 1990;7:319–23.
Huskisson EC. Measurement of pain. Lancet
;2:1127–1131
Cleeland, C. Pain assessment in cancer. in: D. Osoba
(Ed.) Effect of cancer on quality of life. CRC Press, Boca
Raton, FL; 1991: 293–305
Perrot S, Lantéri-Minet M. Patients’ Global Impression
of Change in the management of peripheral
neuropathic pain: Clinical relevance and correlations
in daily practice. Eur J Pain. 2019;23:1117–1128.
Naranjo CA, Busto U, Sellers EM. A method for
estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug; 30(2):239-45
The use of the WHO-UMC system for standardised
case causality assessment. Accessed from http://whoumc.
org/Graphics/24734.pdf . Accessed on January
, 2023
Schumock GT, Thornton JP. Focusing on the
preventability of adverse drug reactions. Hosp Pharm.
Jun;27(6):538.
Hartwig SC, Siegel J, Schneider PJ. Preventability
and severity assessment in reporting adverse drug
reactions. Am J Hosp Pharm. 1992 Sep; 49(9):2229-32
Thompson K, Kukarni J and Sergejew AA. Reliability
and validity of a new Medication Adherence Rating
Scale (MARS) for the psychoses. Schizophr Res., 2000;
(3):241-247
WHO Quality of Life-BREF (WHOQOL-BREF).
Accessed from https://www.who.int/substance_
abuse/research_tools/whoqolbref/en/. Accessed on
January 20, 2020
Devi P, Madhu K, Ganapathy B, Sarma G, John L,
Kulkarni C. Evaluation of efficacy and safety of
gabapentin, duloxetine, and pregabalin in patients
with painful diabetic peripheral neuropathy. Indian J
Pharmacol 2012;44:51-6
Kim HK, Kim JH, Gao X, Zhou JL, Lee I, Chung K,
Chung JM. Analgesic effect of vitamin E is mediated
by reducing central sensitization in neuropathic pain.
Pain. 2006;122(1-2):53-62.
Tan T, Barry P, Reken S, et al. Pharmacological
management of neuropathic pain in nonspecialist
settings: summary of NICE
guidance. BMJ. 2010;340:c1079.
Tütüncü NB, Bayraktar M, Varli K. Reversal of defective
nerve conduction with vitamin E supplementation in
type 2 diabetes: a preliminary study. Diabetes Care.
;21(11):1915-8.
Vitamin E in Neuroprotection Study (VENUS)
Investigators; Hor CP, Fung WY, Ang HA, Lim SC,
Kam LY, Sim SW, Lim LH, Choon WY, Wong JW,
Ch’ng ASH, Beh KKM, Wee HC, Ong LM, Khan NAK,
Sulaiman SAS, Shuaib IL, Bakar A, Yusof Y, Yusof YM,
Abu Bakar F, Tang WS, Teh HL, Wahid NA, Saaidin
S, Idris N, Yoon CK, Ong HN, Ganapathy JT, Loo CE,
Samy MM, Zainal H, Dharan SCS, Ooi BY, Teoh PY,
Tye YL, Yeoh CA, Low DW, Looi I, Yuen KH. Efficacy
of Oral Mixed Tocotrienols in Diabetic Peripheral
Neuropathy: A Randomized Clinical Trial. JAMA
Neurol. 2018;75(4):444-452
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.